FDAnews Device Daily Bulletin

CARDIOGENESIS RECEIVES CE MARK APPROVAL TO MARKET MINIMALLY INVASIVE PLATFORM IN EUROPEAN UNION

Nov. 16, 2005
A A

Cardiogenesis, a leading developer of surgical products and accessories used in angina-relieving procedures, recently announced that it has received CE MARK (Conformite Europeenne) approval for the commercial sale of the Pearl Minimally Invasive TMR delivery systems in European Union member countries. The Pearl Robotic 5.0 and Thoracoscopic 8.0 delivery systems are designed to reduce the morbidity and recovery time for patients, while providing the same improved long term survival and enduring angina benefit achieved with the standard Cardiogenesis Ho:YAG surgical system.
LifeSciencesWorld